Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macupatide and Eloralintide for Weight Management in Obesity or Overweight
NCT07589608Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of macupatide and eloralintide in obesity (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change from Baseline in Body Weight at 36 weeks. Started May 2026; status: recruiting.
02
Drugs
macupatideeloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07589608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589608.